The microscope defined microbiology in the 19th and 20th centuries, but in the 21st century, DNA sequencing will make possible significant advancements. uBiome aims to get big data from bacteria based on its unique technologies.
San Francisco, CA (PRWEB) November 11, 2016
Jessica Richman, PhD, co-founder and CEO of the leading microbial genomics company, uBiome, will present the opening keynote address at the 2016 American Medical Informatics Association’s (AMIA) Annual Symposium, to be held in Chicago from November 12 - 16.
The AMIA and its members aim to transform healthcare through trusted science, education, and practice in biomedical and health informatics.
Jessica Richman, PhD, will join two other keynote speakers at the AMIA Symposium – Patricia Flatley Brennan, RN, PhD, Director of the NIH National Library of Medicine in Bethesda, Maryland and Eric Horvitz, MD, PhD, Technical Fellow and Director of the Microsoft Research Lab in Redmond.
uBiome uses next generation high-throughput DNA sequencing technology to deliver highly detailed analyses of the human microbiome, the ecosystem of trillions of microbes that populate the human body. Microorganisms in the gut play a supporting role in digestion and the synthesis of vitamins, but pathogenic microbes are associated with a range of conditions such as autoimmune disorders, diabetes, heart conditions, Inflammatory Bowel Disease, and skin conditions.
To date, uBiome has sequenced nearly 100,000 samples, the world’s largest microbiome database, and recently launched SmartGut™, the world’s first sequencing-based clinical microbiome screening test. SmartGut enables healthcare providers and patients access to a comprehensive microbiome screening test – with a simple, at-home sample collection – that identifies important commensal and pathogenic microorganisms.
Dr. Jessica Richman says: “The microscope defined microbiology in the 19th and 20th centuries, but in the 21st century, DNA sequencing will make possible significant advancements. uBiome aims to get big data from bacteria based on its unique technologies. At the AMIA Symposium, I’ll describe some of the ways we’ve tackled this at uBiome.”
Dr. Richman co-founded uBiome in 2012. Prior to this, she worked for Google, McKinsey, Lehman Brothers, the Grameen Bank, and top-tier Silicon Valley venture firms. She attended Stanford University, studying economics and interdisciplinary engineering. After receiving a fellowship to Oxford University, she became a Fulbright Scholar and earned her PhD.
Her work has been reported by Wired, MIT Technology Review, Scientific American, NPR, FoxNews, ABC News, and dozens of other media organizations. She has spoken at TEDMED, TEDxBrussels, Partnering for Cures, the American Society for Microbiology, HealthFoo, SciFoo, Oxford University, the University of California San Francisco, and many other conferences and events.
Founded in 2012, uBiome is the world’s leading microbial genomics company. uBiome is funded by Y Combinator, Andreessen Horowitz, 8VC, and other leading investors.
uBiome’s mission is to explore important research questions about the microbiome and to develop accurate and reliable clinical tests based on the microbiome.
Ph: +1 (415) 212-9214